LU93312I2 - Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate - Google Patents

Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate Download PDF

Info

Publication number
LU93312I2
LU93312I2 LU93312C LU93312C LU93312I2 LU 93312 I2 LU93312 I2 LU 93312I2 LU 93312 C LU93312 C LU 93312C LU 93312 C LU93312 C LU 93312C LU 93312 I2 LU93312 I2 LU 93312I2
Authority
LU
Luxembourg
Prior art keywords
salt
migalastat
chlorhydrate
including salt
Prior art date
Application number
LU93312C
Other languages
English (en)
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU93312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of LU93312I2 publication Critical patent/LU93312I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU93312C 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate LU93312I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
PCT/US2007/069046 WO2007137072A2 (fr) 2006-05-16 2007-05-16 Dosages biologiques pour le diagnostic et l'évaluation d'options de traitement de la maladie de fabry

Publications (1)

Publication Number Publication Date
LU93312I2 true LU93312I2 (fr) 2017-01-26

Family

ID=38723987

Family Applications (1)

Application Number Title Priority Date Filing Date
LU93312C LU93312I2 (fr) 2006-05-16 2016-11-16 Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate

Country Status (18)

Country Link
US (9) US7851143B2 (fr)
EP (5) EP2955520B1 (fr)
JP (6) JP2009537149A (fr)
AU (1) AU2007253900A1 (fr)
CA (1) CA2652553C (fr)
CY (3) CY1115180T1 (fr)
DK (2) DK2787345T3 (fr)
ES (3) ES2709445T3 (fr)
HK (3) HK1129458A1 (fr)
HU (2) HUE027569T2 (fr)
LT (1) LTC2787345I2 (fr)
LU (1) LU93312I2 (fr)
MX (2) MX2008014679A (fr)
NL (1) NL300843I2 (fr)
PL (2) PL2533050T6 (fr)
PT (1) PT2533050E (fr)
SI (2) SI2533050T1 (fr)
WO (1) WO2007137072A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955520B1 (fr) 2006-05-16 2018-10-31 Amicus Therapeutics, Inc. Options de traitement pour la maladie de fabry
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (fr) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
DK2252313T3 (en) * 2008-02-12 2015-07-13 Amicus Therapeutics Inc METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES
MX2010009875A (es) * 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
TW201142297A (en) * 2009-11-17 2011-12-01 Baylor Res Inst Urinary triaosylceramide (Gb3) as a marker of cardiac disease
WO2011109448A1 (fr) * 2010-03-05 2011-09-09 Baylor Research Institute Participation de voie de signalisation d'androgènes/du récepteur des androgènes dans maladie de fabry
US20140219986A1 (en) * 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
JP6208122B2 (ja) 2011-05-12 2017-10-04 プロテオステイシス セラピューティクス，インコーポレイテッド プロテオスタシス調節因子
ES2864774T3 (es) * 2011-12-22 2021-10-14 Centogene Ip Gmbh Combinación de un compuesto que tiene la capacidad de reorganizar una enzima lisosomal y Ambroxol y/o un derivado de Ambroxol
AU2013202368B2 (en) 2012-01-25 2016-06-16 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
WO2014127038A1 (fr) * 2013-02-12 2014-08-21 Baylor Research Institute Procédés et compositions associés à l'homéostase du calcium et la maladie de fabry
NZ720499A (en) * 2013-12-23 2020-04-24 Bcn Peptides Sa Bicalutamide analogs or (s)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
JP6770945B2 (ja) * 2014-07-25 2020-10-21 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヒト４−リン酸アダプタータンパク質２糖脂質移行タンパク質様ドメインの結晶構造
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US20190183869A1 (en) * 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
JP2020507562A (ja) 2017-05-30 2020-03-12 アミカス セラピューティックス インコーポレイテッド 腎機能障害を有するファブリー患者の治療方法
EP3630114B1 (fr) * 2017-05-30 2023-11-01 Amicus Therapeutics, Inc. Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
EP3749307A1 (fr) 2018-02-06 2020-12-16 Amicus Therapeutics, Inc. Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes
FI3749308T3 (fi) * 2018-02-06 2024-01-18 Amicus Therapeutics Inc Potilaiden, joilla on klassinen fabryn tauti, hoito migalastaatilla
WO2020006269A1 (fr) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
MA53014A (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics Inc Composés améliorant l'activité du protéasome
WO2020023390A1 (fr) 2018-07-25 2020-01-30 Modernatx, Inc. Traitement enzymatique substitutif basé sur l'arnm combiné à un chaperon pharmacologique pour le traitement de troubles du stockage lysosomal
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11191827B1 (en) 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011353A1 (fr) * 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Alpha-galactosidase de recombinaison, une therapie contre la maladie de fabry
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
WO1997037645A1 (fr) * 1996-04-10 1997-10-16 The Regents Of The University Of California Correction des defaillances genetiques a l'aide de chaperons chimiques
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
ES2619353T3 (es) 2003-01-31 2017-06-26 Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP1633356A1 (fr) * 2003-05-22 2006-03-15 The Hospital for Sick Children Traitement des maladies de tay sachs ou de sandhoff par renforcement de l'activite d'une hexosaminidase
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
BRPI0416217A8 (pt) 2003-11-12 2018-05-08 Amicus Therapeutics Inc composto derivado de hidroxipiperidina, métodos para a síntese de um composto derivado de hidroxipiperidina para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase numa célula de mamífero e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir beta-glicosidade, e para tratar doença de gaucher e derivado hidroxipiperidina com ligante flexível curto
ES2572148T3 (es) 2005-05-17 2016-05-30 Amicus Therapeutics Inc Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
CA2611011C (fr) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Traitement de troubles du snc associes a des mutations dans des genes codant pour des enzymes lysosomales
ES2537089T3 (es) 2005-06-08 2015-06-02 Amicus Therapeutics, Inc. Purificación de imino- y amino-azúcares
NZ565953A (en) 2005-07-27 2012-01-12 Univ Florida Small compounds that correct protein misfolding and uses thereof
WO2007089591A2 (fr) 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions et méthodes pour criblage à haut débit de chaperons pharmacologiques
EP2955520B1 (fr) 2006-05-16 2018-10-31 Amicus Therapeutics, Inc. Options de traitement pour la maladie de fabry
WO2008034628A1 (fr) 2006-09-22 2008-03-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Hemifumarate d'aripiprazole et procede de preparation associe
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (fr) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
DK2252313T3 (en) 2008-02-12 2015-07-13 Amicus Therapeutics Inc METHOD TO PREDICT response to Pharmacological chaperone TREATMENT OF DISEASES
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
TW201142297A (en) 2009-11-17 2011-12-01 Baylor Res Inst Urinary triaosylceramide (Gb3) as a marker of cardiac disease
US20140219986A1 (en) 2011-03-11 2014-08-07 Amicus Therapeutics ,Inc. Dosing regimens for the treatment of fabry disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
EP2874648A4 (fr) 2012-07-17 2015-12-30 Amicus Therapeutics Inc Co-formulation d'alpha-galactosidase a et de 1-désoxygalactonojirimycine
WO2017165164A1 (fr) 2016-03-22 2017-09-28 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs de la mutation g9331a au sein du gène gla
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
TW201829770A (zh) 2017-01-10 2018-08-16 美商阿米庫斯醫療股份有限公司 用於治療fabry氏病之重組α-半乳糖苷酶A
JP2020507562A (ja) 2017-05-30 2020-03-12 アミカス セラピューティックス インコーポレイテッド 腎機能障害を有するファブリー患者の治療方法
SG11202000423XA (en) 2017-07-19 2020-02-27 Amicus Therapeutics Inc Treatment of fabry disease in ert-naïve and ert-experienced patients
SG11202001707PA (en) 2017-08-28 2020-03-30 Amicus Therapeutics Inc Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
FI3749308T3 (fi) 2018-02-06 2024-01-18 Amicus Therapeutics Inc Potilaiden, joilla on klassinen fabryn tauti, hoito migalastaatilla
EP3749307A1 (fr) 2018-02-06 2020-12-16 Amicus Therapeutics, Inc. Utilisation de migalastat pour le traitement de la maladie de fabry chez des patientes enceintes
EP4289476A3 (fr) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de fabry chez les patients porteurs d'une mutation du gène gla
TW202112372A (zh) 2019-06-11 2021-04-01 美商阿米庫斯醫療股份有限公司 治療具有腎損害患者的Fabry氏病之方法
US11833164B2 (en) 2019-08-07 2023-12-05 Amicus Therapeutics, Inc. Methods of treating Fabry disease in patients having a mutation in the GLA gene

Also Published As

Publication number Publication date
HK1178975A1 (en) 2013-09-19
JP2020196717A (ja) 2020-12-10
US9000011B2 (en) 2015-04-07
US20080056994A1 (en) 2008-03-06
LTC2787345I2 (lt) 2017-10-10
CA2652553A1 (fr) 2007-11-29
WO2007137072A3 (fr) 2008-10-16
AU2007253900A1 (en) 2007-11-29
US20180250279A1 (en) 2018-09-06
SI2787345T1 (sl) 2016-08-31
PL2787345T3 (pl) 2016-08-31
EP2024745A2 (fr) 2009-02-18
JP6800176B2 (ja) 2020-12-16
JP2009537149A (ja) 2009-10-29
DK2787345T3 (en) 2016-05-30
ES2464527T3 (es) 2014-06-03
JP7175297B2 (ja) 2022-11-18
US11241422B2 (en) 2022-02-08
LTPA2016033I1 (lt) 2016-12-12
JP2016006088A (ja) 2016-01-14
PL2533050T3 (pl) 2014-08-29
EP2955520A1 (fr) 2015-12-16
DK2533050T3 (da) 2014-06-02
HUS1600048I1 (hu) 2017-01-30
EP2533050B1 (fr) 2014-03-12
EP2955520B1 (fr) 2018-10-31
ES2464527T7 (es) 2015-09-14
US20170042868A1 (en) 2017-02-16
MX2008014679A (es) 2009-04-14
EP2533050B3 (fr) 2015-06-24
CY2016040I1 (el) 2017-06-28
WO2007137072A2 (fr) 2007-11-29
US9480682B2 (en) 2016-11-01
US10383864B2 (en) 2019-08-20
US20150238474A1 (en) 2015-08-27
MX351004B (es) 2017-09-26
US7851143B2 (en) 2010-12-14
EP2787345B8 (fr) 2016-04-13
US9987263B2 (en) 2018-06-05
EP3457135A1 (fr) 2019-03-20
CA2652553C (fr) 2020-08-18
PL2533050T6 (pl) 2016-05-31
JP2013100307A (ja) 2013-05-23
US20220160690A1 (en) 2022-05-26
CY1117656T1 (el) 2017-05-17
DK2533050T6 (da) 2015-09-21
US10406143B2 (en) 2019-09-10
PT2533050E (pt) 2014-05-26
HUE027569T2 (en) 2016-10-28
HK1218955A1 (zh) 2017-03-17
JP2018138564A (ja) 2018-09-06
US20180325881A1 (en) 2018-11-15
EP2787345A1 (fr) 2014-10-08
HK1129458A1 (en) 2009-11-27
US20110104727A1 (en) 2011-05-05
ES2464527T9 (es) 2015-07-24
ES2573498T3 (es) 2016-06-08
SI2533050T1 (sl) 2014-07-31
US20190388409A1 (en) 2019-12-26
EP2024745A4 (fr) 2010-03-17
ES2709445T3 (es) 2019-04-16
EP2533050A1 (fr) 2012-12-12
JP2023027053A (ja) 2023-03-01
NL300843I2 (fr) 2016-12-21
CY2016040I2 (el) 2017-06-28
JP6026268B2 (ja) 2016-11-16
CY1115180T1 (el) 2016-12-14
EP2787345B1 (fr) 2016-02-24
EP2024745B1 (fr) 2015-07-08
US20120220632A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
LU93312I2 (fr) Migalastat ou un sel de celui-ci, y compris le sel de chlorhydrate
LU92568I2 (fr) Siméprévir, ou un sel de celui-ci, y compris le sodium siméprévir
LU93327I2 (fr) Opicapone ou un sel pharmaceutiquement acceptable de celui-ci
LU92672I2 (fr) Fluralaner ou un de ses sels
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
LU92785I2 (fr) Céritinib ou un sel pharamceutiquement acceptable de celui-ci
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
DE602006009921D1 (de) Pigmentierter keramischer Körper
BRPI0720547A2 (pt) Inibidores de metaloprotease derivada de heterocíclico
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
ITMI20061048A1 (it) Procedimento per la preparazione di magnesio boroidruro cristallino
DE502007003774D1 (de) Werkzeugaufnahme
BRPI0821067A2 (pt) Compostos de metóxi-imino e composição fungicida compreendendo os mesmos.
FR2901304B1 (fr) Volet roulant ou similaire
FR2877833B1 (fr) Correcteur de lordoses
FR2919887B1 (fr) Ferrure de type cremone ou cremone-serrure
ITMI20080888A1 (it) Procedimento per la preparazione di zileuton
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ES1061996Y (es) Arado de laboreo entre cepas.
FR2911479B1 (fr) Ensemble de vetements.
FR2937125B1 (fr) Determination de grandeurs mesurables geolocalisees.
FR2900262B1 (fr) Portillon de securite
ITCA20060014A1 (it) Raviolo di pompia o arrabiorheddu de pompia
FI20070874A0 (fi) Lämpötiili